A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

BACKGROUND: Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized double-blind clinical trial, utilized a Bayesian design with response-adaptiv...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Alzheimers Res Ther
Main Authors: Swanson, Chad J., Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y. K., Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A., Berry, Scott, Gordon, Robert, Kramer, Lynn D., Cummings, Jeffrey L.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2021
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053280/
https://ncbi.nlm.nih.gov/pubmed/33865446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-021-00813-8
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker